Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||transitional cell carcinoma||not applicable||Nivolumab||FDA approved||Actionable||In a Phase II trial (CheckMate 275) that supported FDA approval, treatment with Opdivo (nivolumab) resulted in objective response in 19.6% (52/265) of urothelial carcinoma patients with prior platinum therapy, with complete response in 2% (6/265), and partial response in 17% (46/265) of patients (PMID: 28131785; NCT02387996).||detail... 28131785|